ReviewStem cells international2026
Efficacy of Fetal MSC Therapy for Osteogenesis Imperfecta: A Systematic Review and Meta-Analysis in Mice.
Review in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteogenesis imperfecta (OI) is a genetic disorder marked by collagen defects that cause skeletal fragility. Current treatments improve bone density but not bone quality or fracture rates. Fetal mesenchymal stem cells (fMSCs) show superior osteogenic and immunomodulatory potential compared with adult mesenchymal stem cells (MSCs) and may offer a disease-modifying therapy. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, we systematically reviewed preclinical murine studies assessing the use of fMSC transplantation for OI. Data from eligible studies were pooled using random-effects meta-analysis (Hartung-Knapp adjustment). Risk ratios (RRs) were used for fracture incidence and standardized mean differences (SMDs) for mechanical and structural outcomes. Results: Four studies (219 mice: 91 treated, 128 controls) met inclusion criteria. fMSC treatment significantly reduced total long-bone fracture incidence (RR = 0.30; 95% confidence interval [CI]: 0.13-0.72; Conclusions: fMSC transplantation significantly reduces fracture burden and shows consistent trends toward improved bone structure and strength in OI murine models. These findings support the need for further standardized, multicenter studies to optimize cell delivery, enhance engraftment, and validate clinical efficacy in humans. However, given the small evidence base, lack of independent replication, and reliance on a single OI mouse model, these findings should be interpreted as exploratory and hypothesis-generating rather than confirmatory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.